Core Insights - OrthoPediatrics Corp. has successfully completed the first U.S. surgical procedures using the VerteGlide Spinal Growth Guidance System to treat Early Onset Scoliosis (EOS) [1][2] Company Overview - OrthoPediatrics, founded in 2006, focuses exclusively on pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions [5] - The company markets over 80 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [5] - OrthoPediatrics distributes its products in the United States and over 70 countries globally [5] Product Details - The VerteGlide system is part of OrthoPediatrics' Scoliosis suite and provides a unique alternative for treating scoliosis, leveraging advanced implant and instrument technology [3] - This system addresses complex spinal pathologies in early onset scoliosis patients and is designed with input from a team of expert surgeons [4] - The technology behind VerteGlide is based on Shilla™ technology licensed from Medtronic [4] Clinical Impact - The initial procedures using VerteGlide have been reported as a great success, addressing a significant unmet clinical need for EOS patients [2] - The system is expected to greatly benefit current and future patients, providing a cutting-edge solution for complex spinal conditions [2][4] Upcoming Events - VerteGlide will be featured at the 60th Annual Meeting of the Scoliosis Research Society in September and the 19th International Congress on Early Onset Scoliosis in November [3]